133
Participants
Start Date
July 1, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Participants will be administered with FDC tablets once daily.
Akershus University Hospital, Lørenskog
UZ Leuven, Leuven
DEOEC II. sz. Belgygyszati Klinika, Debrecen
Royal Adelaide Hospital, Adelaide
Flinders Medical Centre, Bedford Park
Hospital ClinicUniversity of Barcelona, Barcelona
University Hopital Santaros klinikos, Vilnius
NYU Langone Health, New York
Research Site SRO, Pilsen
Piedmont Atlanta Hospital, Atlanta
Medizinische Hochschule Hannover, Hanover
Tampa General Medical Group, Tampa
University of Alabama at Birmingham, Birmingham
East Tennessee Research Institute, Johnson City
Gastro One, Germantown
University Hospital of Larissa, Larissa
Kyungpook National University Hospital, Daegu
University Hospitals Cleveland Medical Center, Cleveland
Consorcio Hospital General Universitario, Valencia
Hepato-Gastroenterologie HK, s.r.o., Hradec Králové
Tartu University Hospital, Tartu
CHRU de Lille, Lille
Ochsner Clinic Foundation, New Orleans
CHU Paris Est - Hopital Saint Antoine, Paris
Hopital de la Pitie Salpetriere, Paris
The Liver Institute at Methodist Dallas Medical Center, Dallas
Houston Methodist Hospital, Houston
American Research Corporation, San Antonio
Southern California Research Center, Coronado
Hopital Henri Mondor, Créteil
Artroscan s.r.o. Gastroenterologicka, Ostrava
Hadassah Ein-Karem Medical Center - Liver unit, Jerusalem
Beth Israel Deaconess Medical Center, Boston
DIM Clinica Privada, Buenos Aires
Hospital Italiano de Buenos Aires, Buenos Aires
Hospital Italiano de La Plata, Buenos Aires
Hospital Universitario Austral, Buenos Aires
Hospital Provincial del Centenario, Santa Fe
University of Alberta Division of Gastroenterology Zeidler Ledcor Centre, Edmonton
Pacific Gastroenterology Associates GI Research Institute, Vancouver
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna
Hacettepe University, Faculty of Medicine, Adult Hospital Gastroenterology, Ankara
Ege University, Faculty of Medicine, Gastroenterology, Bornova
Istanbul University, Capa Faculty of Medicine, Gastroenterology, Istanbul
Harran University Hospital, Gastroenterology, Sanliurfa
Universityl Hospital Dubrava, Zagreb
Academisch Medisch Centrum, Amsterdam
Seoul National University Bundang Hospital, Seongnam-si
Hull University Teaching Hospitals NHS Trust, Hull
Institute of Cellular Medicine Newcastle University, Newcastle upon Tyne
John Radcliffe Hospital, Oxford
Lead Sponsor
Intercept Pharmaceuticals
INDUSTRY